 ImmunityBio Inc NASDAQ: IBRX has reported initial data from the Phase 1 study evaluating its hAd5 COVID-19 vaccine candidate in healthy participants. Just 14-16 days after the single dose of the vaccine, the mean level of T cells generated in response to dual antigen hAd5 spike S nucleocapsid N vaccine was ten times higher for N specific T cells. 